CBLL (45) TMDX (62) INMD (58) AXGN (54) ⌘ Pro Terminal →

CONMED Corporation (CNMD) — RQD Stock Rating Cockpit

$45.72 -0.09% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $45.63

CONMED Corporation (CNMD) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $1.36B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CNMD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CNMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, CONMED Corporation (NYSE: CNMD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $45.72 (-0.09% 1D, market cap $1.36B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, CNMD ranks #127 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CNMD compare to CBLL and TMDX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), CNMD carries a Roarable C (65/100 RQD), trailing P/E of 28.9x, gross margin of 54.6%, and ROIC of 7.8%. By comparison, CBLL (CeriBell Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $1.07B) and TMDX (TransMedics Group Inc.) posts a C grade (62/100 RQD, P/E 12.2x, ROIC 18.1%, cap $2.33B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CNMD?

▼

Per CNMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000816956), CONMED Corporation generated $1.37B in revenue (+5.2% YoY), $47.1M in net income, and $150.9M in free cash flow against $2.33B in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $45.62 (-0.21%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 11% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY • 55.6% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE+3.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CNMD)Realized 20D OHLCV Swing Band: ±8.9%

Deterministic 5-Pillar Attribution (65/100 Composite)

🔍 WHY CNMD SCORES 65/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (22% of score)

Altman Z-Score 1.91 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning10/20 pts (-10 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-10 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$45.36+1.5% Next Q

Q2 (-2Q)

Grade C$46.05+3.5% Next Q

Q3 (-1Q)

Grade C+$47.68-4.1% Next Q

Current

Grade C$45.72+1.3% Hist 90D α

Trajectory: C (57) → C (65)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CNMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 65/100 (C) score, CNMD faces multiple-compression risk if 28.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 52.1% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($46.97) or 200D SMA ($41.43) invalidates the momentum regime and cuts Target Base ($47.16) toward Bear Floor ($36.78).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CNMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CNMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 65%NO 35%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

47.130 Oversold · 70 Hot

ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)

1.91>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE64% OF RANGE

L: $31$45.72H: $54

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (55% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: CRQD 13 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: CRQD 25 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C+RQD 27 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on CNMD

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (65)

7.8% ROIC with 54.6% gross margin and 11.07% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (70)

Altman-Z 1.91 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (63)

25/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like CNMD

✓Company leadership has skin in the game with net positive insider conviction.

Bear Case: What Could Go Wrong

!Broader market pullbacks can still drag down strong stocks in the short run.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (CNMD Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CNMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +27.42%🛡️ HOLDING TREND SUPPORT

2026-11-02O $45.76H $45.76L $45.72C $45.72VOL 482.2K

RES: $49.40SUP: $43.77SMA50: $46.97SMA200: $41.43

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CNMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CNMD Butterfly Map → + Track CNMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

22.2%/yr Implied 5Y Growth

vs. +5.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CNMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CNMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CNMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CNMD)

Health Care Rank #127 of 1016 ⚔️ CBLL vs CNMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CNMD vs. CBLL, TMDX, INMD, AXGN)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, CONMED Corporation (CNMD) ranks #127 by composite RQD confidence (65/100, grade C) and #318 by equity capitalization ($1.36B). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. CNMD currently leads its immediate peer cohort in composite quantitative strength at 65/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CNMD ACTIVE CONMED Corporation	C	65/100	28.9x	54.6%	7.8%	-0.09%	$1.36B	Benchmark Subject
CBLL CeriBell Inc.	D	45/100	—	87.9%	-35.0%	+2.20%	$1.07B	/cbll-vs-cnmd →
TMDX TransMedics Group Inc.	C	62/100	12.2x	59.9%	18.1%	+0.33%	$2.33B	/tmdx-vs-cnmd →
INMD InMode Ltd.	D+	58/100	—	78.5%	17.7%	+1.05%	$776.6M	/inmd-vs-cnmd →
AXGN Axogen Inc.	D+	54/100	—	74.3%	-2.6%	+0.77%	$2.96B	/axgn-vs-cnmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000816956

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CONMED Corporation (CNMD) reported GAAP revenue of $1.37B (+5.2% vs. FY2024 revenue of $1.31B , and +10.4% cumulative change since FY2023) , GAAP net income of $47.1M, operating cash flow of $170.7M, and free cash flow of $150.9M (-2.0% YoY). On the balance sheet, CNMD closed FY2025 with $2.33B in total assets against $0 in total debt (Altman Z-Score: 1.91, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.37B	$47.1M	$170.7M	$150.9M	$2.33B	—
FY2024 (FY)	2024-12-31	$1.31B	$132.4M	$167.0M	$153.9M	$2.31B	—
FY2023 (FY)	2023-12-31	$1.24B	$64.5M	$125.3M	$125.3M	—	—

3. CNMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CNMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CNMD compare to CBLL and TMDX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CNMD?

Where is CNMD trading relative to its 50-day, 200-day, and 52-week technical levels?

CNMD last traded at $45.72 (-0.09% on volume of 482,213 shares), positioning the stock -2.66% below its 50-day simple moving average ($46.97) and +10.35% above its 200-day simple moving average ($41.43). Across its 52-week range of $31.44 to $53.66, CNMD sits at the 64.3% percentile with a 14-day RSI of 47.1 (NEUTRAL RANGE) and an implied next-earnings move of ±8.9% ($41.65 to $49.79).

CNMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell CNMD stock right now?

CONMED Corporation (CNMD) currently earns a Roarable Rating of C (Hold — HOLD) with 65/100 RQD Confidence. Solid 55% profit margin (8% return on capital), mixed timing at 29x P/E—hold if owned, no rush to chase.

What is CNMD's 12-month price target and RQD AI Jury consensus?

CNMD's 12-month base price target is $47.16 (range $36.78 to $56.34), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: CNMD RQD Cockpit CNMD 12M Forecast CNMD Earnings & Move CNMD Dividends & DRIP CNMD Insiders & 13F CNMD Whale Options CNMD Profit Sankey CNMD News & Why